Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Relationship between cognitive functions and serum neurotrophic factor levels in long-term hospitalized male patients with schizophrenia.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: BioMed Central Country of Publication: England NLM ID: 100968559 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-244X (Electronic) Linking ISSN: 1471244X NLM ISO Abbreviation: BMC Psychiatry Subsets: MEDLINE
- Publication Information:
Original Publication: London : BioMed Central, [2001-
- Subject Terms:
- Abstract:
Competing Interests: Declarations. Ethics approval and consent to participate: We declare that all experiments on human subjects were conducted in accordance with the Declaration of Helsinki and that all procedures were carried out with the adequate understanding and written consent of the subjects. All experimental protocols were approved by the Ethics Committee of WuTaiShan Hospital of Yangzhou University. Informed consent was obtained from all the participants and/or their legal guardians. All methods were carried out in accordance with relevant guidelines and regulations. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Objective: This study explored the changes in serum neurotrophic factor levels, the status of cognitive function, event-related potential P300, and the relationships between serum neurotrophic factor levels and cognitive functions, as well as event-related potential P300 in male schizophrenia patients with long-term hospitalization.
Methods: A total of 82 male schizophrenia patients with long-term hospitalization and 52 healthy controls were recruited. Cognitive functions were evaluated in all participants, including verbal fluency function, attention function, executive function, and spatial function. Event-related potential P300 latency and amplitude were recorded using the Nicolet Viking Quest evoked potential system (USA). The serum levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) were measured in all participants using enzyme-linked immunosorbent assay (ELISA).
Results: The patient group exhibited significantly poorer performance in all cognitive functions compared to the control group (p < 0.05). The patient group exhibited a statistically significant prolongation in P300 latency and a reduction in P300 amplitude compared to the control group (P < 0.01). In addition, serum BDNF levels were significantly lower in the patient group (9.1 ± 2.1 ng/ml) compared to the control group (11.6 ± 2.3 ng/ml, P < 0.01). Serum GDNF levels were 603.4 ± 182.6 pg/ml in the patient group and 610.2 ± 176.3 pg/ml in the control group, showing no statistically significant difference (P > 0.05). Onset levels were significantly correlated with almost all cognitive functions. BDNF levels were correlated to digital cancellation test scores (P < 0.05) and trail making test part B (TMT-part B) scores (P < 0.05). Moreover, a correlation was found between GDNF levels and block design test scores (P < 0.05). The latency of P300 was correlated to digital cancellation test scores (P < 0.01) and trail making test part A (TMT-part A) scores (P < 0.05). The amplitude of P300 was correlated with digital cancellation test scores (P < 0.01).
Conclusions: This study reveals that patients with chronic schizophrenia suffer from notable cognitive deficits during long-term hospitalization, which is linked to specific clinical characteristics. The patient group exhibited significantly lower serum BDNF levels than the control group. Event-related potential P300 testing revealed prolonged latency and reduced amplitude in patients. Serum BDNF and GDNF levels were selectively correlated with specific cognitive function performance.
(© 2025. The Author(s).)
- References:
Schizophr Res. 2010 Jun;119(1-3):47-51. (PMID: 20096541)
Psychol Med. 2019 Aug;49(11):1929-1936. (PMID: 30226125)
Mol Psychiatry. 2003 Jun;8(6):592-610. (PMID: 12851636)
Int J Neuropsychopharmacol. 2010 May;13(4):535-9. (PMID: 19941699)
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt C):168-176. (PMID: 28666826)
Mol Psychiatry. 2015 Sep;20(9):1108-19. (PMID: 25266124)
J Clin Psychopharmacol. 2011 Jun;31(3):334-6. (PMID: 21508862)
Behav Brain Res. 2014 Nov 1;274:1-9. (PMID: 25101543)
Schizophr Res. 2024 Jun;268:205-222. (PMID: 37788946)
Front Psychiatry. 2020 Jul 30;11:731. (PMID: 32848912)
World J Psychiatry. 2016 Mar 22;6(1):84-101. (PMID: 27014600)
Eur J Neurosci. 1994 Apr 1;6(4):668-71. (PMID: 8025717)
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 2;76:163-168. (PMID: 28342945)
Neurobiol Aging. 2008 Sep;29(9):1366-79. (PMID: 17399854)
Schizophr Res. 2008 Apr;101(1-3):320-30. (PMID: 18321680)
BMC Psychiatry. 2021 Nov 11;21(1):562. (PMID: 34763683)
JAMA Psychiatry. 2013 Mar;70(3):261-70. (PMID: 23325066)
Psychiatry Res. 2016 Dec 30;246:617-622. (PMID: 27836239)
Lancet. 2022 Jan 29;399(10323):473-486. (PMID: 35093231)
Eur Neuropsychopharmacol. 2014 Jan;24(1):133-41. (PMID: 24314852)
Acta Neurobiol Exp (Wars). 2015;75(3):314-25. (PMID: 26581387)
J Affect Disord. 2011 Aug;132(3):418-21. (PMID: 21524799)
Cogn Affect Behav Neurosci. 2014 Mar;14(1):161-74. (PMID: 24037621)
N Engl J Med. 2019 Oct 31;381(18):1753-1761. (PMID: 31665579)
Schizophr Bull. 1987;13(2):261-76. (PMID: 3616518)
Psychophysiology. 2003 Sep;40(5):684-701. (PMID: 14696723)
Neuropharmacology. 1999 Jun;38(6):913-6. (PMID: 10465695)
Psychopharmacology (Berl). 2012 Jul;222(2):277-84. (PMID: 22274000)
Neurosci Lett. 2014 Jul 11;575:37-41. (PMID: 24861509)
Eur Psychiatry. 2015 Feb;30(2):198-204. (PMID: 25543333)
Adv Ther. 2012 Feb;29(2):148-62. (PMID: 22351433)
Schizophr Bull. 2017 May 1;43(3):546-556. (PMID: 27521348)
Brain Res Bull. 2012 Aug 1;88(5):454-9. (PMID: 22498307)
Prog Neuropsychopharmacol Biol Psychiatry. 2024 Jan 10;128:110867. (PMID: 37783265)
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1308-11. (PMID: 18502013)
Schizophr Res. 2001 Oct 1;52(1-2):79-86. (PMID: 11595394)
Schizophr Bull. 2014 May;40(3):516-22. (PMID: 24574307)
Psychol Med. 2021 Jul;51(9):1570-1580. (PMID: 32156323)
Neurosci Biobehav Rev. 2011 Jan;35(3):573-88. (PMID: 20620163)
Int J Psychophysiol. 2012 Oct;86(1):108-13. (PMID: 22771850)
Learn Mem. 2003 Mar-Apr;10(2):86-98. (PMID: 12663747)
Brain Behav Immun. 2013 Aug;32:105-11. (PMID: 23499732)
Pharmacol Biochem Behav. 2023 Apr;225:173554. (PMID: 37030547)
Mol Psychiatry. 2023 May;28(5):1902-1918. (PMID: 36690793)
Schizophr Res Cogn. 2021 Dec 21;28:100233. (PMID: 35004189)
Schizophr Res. 2005 May 1;74(2-3):253-61. (PMID: 15722004)
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jun 3;51:99-104. (PMID: 24468644)
Biol Psychiatry. 2020 Aug 15;88(4):294-303. (PMID: 32507388)
Expert Rev Neurother. 2010 Jan;10(1):43-57. (PMID: 20021320)
Schizophr Bull. 2019 Sep 11;45(5):1068-1080. (PMID: 30753731)
Neuropsychol Rehabil. 2019 Oct;29(9):1475-1487. (PMID: 29212415)
Eur J Neurosci. 2001 Oct;14(7):1153-63. (PMID: 11683907)
- Grant Information:
2023KY1126 Zhejiang Medical and Health Science and Technology Project; 2023ZL668 Zhejiang Traditional Chinese Medicine Science and Technology Project; Szlcyxzx202109 Suzhou Clinical Medical Center for Mood Disorders; SZS2024016 Suzhou Key Laboratory; DZXYJ202413 Multicenter Clinical Research on Major Diseases in Suzhou
- Contributed Indexing:
Keywords: Schizophrenia; BDNF; Cognitive functions; Event-related potentials; GDNF; Neurotrophic factors
- Accession Number:
0 (Brain-Derived Neurotrophic Factor)
0 (Glial Cell Line-Derived Neurotrophic Factor)
7171WSG8A2 (BDNF protein, human)
0 (GDNF protein, human)
- Publication Date:
Date Created: 20250727 Date Completed: 20250727 Latest Revision: 20250731
- Publication Date:
20250731
- Accession Number:
PMC12291289
- Accession Number:
10.1186/s12888-025-07173-9
- Accession Number:
40713548
No Comments.